• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	Apimeds Pharmaceuticals US, Inc. (APUS)
	Q2-CY2026	Q1-CY2026	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014
Balance Sheet Date		2026-Mar-31	2025-Dec-31	2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31
Fiscal Period		Q1-FY2026	Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024
Total Revenue					9,518$
QoQ%
YoY%
Cost Of Revenue					0$
Gross Profit					9,518$
Gross Margin					100.00%
Operating Expenses		12,185,694$	7,040,051$	1,844,239$	2,663,904$	364,368$	275,613$	299,999$	427,757$	271,726$
Operating Income		(12,185,694$)	(7,040,051$)	(1,844,239$)	(2,663,904$)	(364,368$)	(275,613$)	(299,999$)	(427,757$)	(271,726$)
Operating Margin					(27,988.07%)
Interest Income		7$	35,919$	56,426$	15,247$	3$	30$	116$	517$	2,161$
Interest Expenses
Income Before Tax		(35,059,852$)	(1,155,292$)	(1,781,255$)	(2,662,193$)	(402,397$)	(311,633$)	(332,521$)	(449,363$)	(296,473$)
Tax Expenses
Net Income		(35,059,852$)	(1,155,292$)	(1,781,255$)	(2,662,193$)	(402,397$)	(311,633$)	(332,521$)	(449,363$)	(296,473$)
Profit Margin					(27,970.09%)
TTM
Earnings to Minority
Earnings to Common Shareholders		(35,059,852$)	(1,155,292$)	(1,781,255$)	(2,662,193$)	(402,397$)	(311,633$)	(332,521$)	(449,363$)	(296,473$)
QoQ%		(2,934.72%)	35.14%	33.09%	(561.58%)	(29.13%)	6.28%	26.00%	(51.57%)
YoY%		(8,612.75%)	(270.72%)	(435.68%)	(492.44%)	(35.73%)
Earnings Per Share, Basic		(2.26$)	(0.09$)	(0.14$)	(0.26$)	(0.05$)	(0.04$)	(0.04$)	(0.06$)	(0.04$)
Earnings Per Share, Diluted		(2.26$)	(0.09$)	(0.14$)	(0.26$)	(0.05$)	(0.04$)	(0.04$)	(0.06$)	(0.04$)
Unlevered FCF Per Share, Basic		(0.13$)	(0.30$)	(0.14$)	(0.32$)	0.00$	(0.01$)	(0.02$)	(0.02$)	(0.03$)
Unlevered FCF Per Share, Diluted		(0.13$)	(0.30$)	(0.14$)	(0.32$)	0.00$	(0.01$)	(0.02$)	(0.02$)	(0.03$)
Average Shares, Basic		15,513,389	12,678,668	12,575,983	10,369,127	7,903,850	7,903,850	7,903,850	7,903,850	7,903,850
Average Shares, Diluted		15,513,389	12,678,668	12,575,983	10,369,127	7,903,850	7,903,850	7,903,850	7,903,850	7,903,850
EBIT		(35,059,852$)	(1,155,292$)	(1,781,255$)	(2,662,193$)	(402,397$)	(311,633$)	(332,521$)	(449,363$)	(296,473$)
EBITDA		(35,059,852$)	(1,155,292$)	(1,781,255$)	(2,662,193$)	(402,397$)	(311,633$)	(332,521$)	(449,363$)	(296,473$)

Copy Table ✓